Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

Despite the relative success of chemotherapy for Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), novel therapeutic agents are needed for refractory or relapsed patients. Targeted immunotherapy has emerged as a novel treatment option for these patients. Although unconjugated...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xueyan, Soma, Lorinda A, Fromm, Jonathan R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872218/
https://www.ncbi.nlm.nih.gov/pubmed/24379682
http://dx.doi.org/10.2147/OTT.S39107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872218/
https://www.ncbi.nlm.nih.gov/pubmed/24379682
http://dx.doi.org/10.2147/OTT.S39107

Ejemplares similares